ProQR Therapeutics (PRQR) Debt to Equity (2021 - 2025)

ProQR Therapeutics' Debt to Equity history spans 4 years, with the latest figure at $0.05 for Q4 2024.

  • For Q4 2024, Debt to Equity fell 50.11% year-over-year to $0.05; the TTM value through Dec 2024 reached $0.05, down 50.11%, while the annual FY2024 figure was $0.05, 50.11% down from the prior year.
  • Debt to Equity for Q4 2024 was $0.05 at ProQR Therapeutics, down from $0.1 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.39 in Q4 2021 and bottomed at $0.05 in Q4 2024.
  • The 4-year median for Debt to Equity is $0.1 (2022), against an average of $0.16.
  • The largest annual shift saw Debt to Equity plummeted 73.72% in 2022 before it increased 2.12% in 2023.
  • A 4-year view of Debt to Equity shows it stood at $0.39 in 2021, then tumbled by 73.72% to $0.1 in 2022, then increased by 2.12% to $0.1 in 2023, then plummeted by 50.11% to $0.05 in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Debt to Equity are $0.05 (Q4 2024), $0.1 (Q4 2023), and $0.1 (Q4 2022).